persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC) Meeting Abstract
| Authors: | Müller, V.; Turner, N.; Jhaveri, K.; Bardia, A.; Niikura, N.; Diéras, V.; Barrios, C.; Im, S. A.; Bellet, M.; Chang, C. W.; Ross, G.; Patre, M.; Loi, S. |
| Abstract Title: | persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC) |
| Meeting Title: | 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 45 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Nov 13-16 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2022-11-01 |
| Start Page: | 24 |
| Language: | English |
| ACCESSION: | WOS:000883051700045 |
| PROVIDER: | wos |
| DOI: | 10.1159/000521004 |
| Notes: | Meeting Abstract: 283 -- Source: Wos |
